Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-Simon Cancer Center, Indianapolis, Indiana, USA.
Cell Cycle. 2010 Aug 15;9(16):3227-32. doi: 10.4161/cc.9.16.12605. Epub 2010 Aug 4.
Several nucleolar proteins, such as ARF, ribosomal protein (RP) L5, L11, L23 and S7, have been shown to induce p53 activation by inhibiting MDM2 E3 ligase activity and consequently to trigger cell cycle arrest and/or apoptosis. Our recent study revealed another nucleolar protein called nucleostemin (NS), a nucleolar GTP binding protein, as a novel regulator of the p53-MDM2 feedback loop. However, unlike other known nucleolar regulators of this loop, NS surprisingly plays a dual role, as both up and downregulations of its levels could turn on p53 activity. Here, we try to offer some prospective views for this unusual phenomenon by reconciling previously and recently published studies in the field in hoping to better depict the role of NS in linking the p53 pathway with ribosomal biogenesis during cell growth and proliferation as well as to propose NS as another potential molecular target for anti-cancer drug development.
几种核仁蛋白,如 ARF、核糖体蛋白(RP)L5、L11、L23 和 S7,已被证明通过抑制 MDM2 E3 连接酶活性来诱导 p53 激活,从而引发细胞周期停滞和/或细胞凋亡。我们最近的研究揭示了另一种核仁蛋白称为核干细胞蛋白(NS),它是一种核仁 GTP 结合蛋白,作为 p53-MDM2 反馈回路的新型调节剂。然而,与该回路的其他已知核仁调节剂不同,NS 出人意料地发挥双重作用,因为其水平的上调和下调都可以激活 p53 活性。在这里,我们试图通过整合该领域之前和最近发表的研究来提供一些前瞻性观点,希望更好地描述 NS 在将 p53 途径与细胞生长和增殖过程中的核糖体生物发生联系起来的作用,并提出 NS 作为另一种潜在的抗癌药物开发的分子靶标。